After the Télésanté startups Recently lost the ability to sell exact copies of patented drugs as far as weight loss GLP-1. age.
Originally sold by Novo Nordisk under the Victroza and Saxenda brand names, the drug has been available in generic form in the United States since last year. Like ozempic, Liraglutide is an agonist from GLP-1 who imitates a natural hormone and works by removing hunger signals and regulating insulin levels. But it does not have the same recognition or the same popularity as the new GLP-1 drugs for a very simple reason: it does not work as well, can cause more serious side effects, and patients must inject it daily rather than every week.
The FDA determined earlier this year than patented drugs like Zepound and Ozempic were no longer shortage, putting an end to the provisions that allowed online clinics to sell out -of -brand versions of drugs. While clinics and manufacturers finish sales of these compounds, many online clinics and manufacturers adopt Liraglutide. Hims Télésanty led added Generic Liraglutide at its range last month, joining more than a dozen competitors already offering the product in composed, generic or brand form.
Large composition pharmacies, such as Olympia Pharmaceuticals, based in Florida, are already producing drugs, expecting demand to increase. “We have signed large enough contracts for the Liraglutide,” said financial director Joshua Fritzler. “We can treat it in a way in the same way as we have treated semaglutide and shooting”, the active ingredients of Ozempic and Zepbound. Fritzler says Olympia plans to start accelerating production this summer.
GLP-1 drugs like Ozempic and Zepbound have been announced for their unprecedented success in the treatment of obesity and type 2 diabetes. Researchers believe that they also have the potential to help patients with a wide variety of other conditions, of drug addiction to Parkinson. After the GLP-1 demand exploded in recent years, the FDA said that some of the brand’s versions are officially shortened. This meant that doctors could legally prescribe cheaper “composed” versions of the semaglutide and shooting with the same active ingredients as the originals.
Composition pharmacies and remote charts prospered by selling these online alternative GLP-1 products, attracting millions of customers who could not afford or want to pay higher prices for brand medicines, which are often not covered by insurance. Now the shortages for these two drugs have ended. The FDA grace period for manufacturers to stop producing and selling compound shooting is over, and the semaglutide date is May 22. Liraglutide, however, has been in shortage Since April 2023, the compounds are therefore free to continue to do so.
Certain telehealth companies continue to offer aggravated drugs which, according to them, are not technically direct copies of patented drugs because they are available in personalized doses or with additional vitamins. Eli Lilly has already continued some, alleging that these versions are illegal. Other companies and compounds of Télésanté play safely, which would completely cease sales. (Olympia, for example, stops semaglutide production.)
